Fellowships from NCC are established at $40,000 per annum for post-doctoral awards, and are awarded annually. Fellowships are intended for applicants under age 35 with less than two years of post- doctoral laboratory experience, except in extenuating circumstances. Fellowships are also limited to applicants having received no more than one prior fellowship or one career development award. Individuals receiving concurrent support from another organization are not eligible to apply.
Preference will be given to studies that have direct relevance to the diagnosis and treatment of human cancer.
Fellowship awards are not necessarily restricted to salary. Depending on the circumstances, part of the funds may be used for supplies or other valid expenses, which should be listed in the proposed budget. NCC reserves the right to delete any item it deems inappropriate.
The fellowship may be transferable upon application and review, in the event that the fellow leaves the sponsoring organization.
Fellowships generally are extended for a second year. However, adequate progress must have been demonstrated during the first year as evidenced through a progress report submitted with renewal application. Awards are limited to one per laboratory. There can be several different applications if they are on different topics. However, only one award could be made per lab in any round of applications.
NCC fellowship grants do not include funds for institutional overhead and a statement by the institution accepting this condition is required.
National Cancer Center 2019/2020 Grants
The following post-doc fellowship grants and renewals were approved for 2019/2020
Polina Vaitsenfeld, Ph.D.
The Rockefeller University, NY, NY
PROJECT: Enhancing antibody-mediated immunity against tumor-associated carbohydrate antigens
Darko Barisic, Ph.D.
Weill Medical College of Cornell Univ
PROJECT: Role of chromatin remodeling complex BAF in lymphomagenesis
Manoela Tiago dos Santos, Ph.D.
Thomas Jefferson University, Philadelphia, PA
PROJECT: BET inhibition to optimize BRAFi/MEKi therapy for mutant BRAF
Yuanfan Yang, M.D.
Duke Univ Medical Center, Durham, NC
PROJECT: Anti-tumor efficacy of EGFR-targeting immunotoxin in combination with CCNU or PD-L1 blockade in glioma mouse models
Yuanyuan Li, Ph.D.
Icahn School of Medicine at Mt Sinai
PROJECT: IRAK1 Kinase drives cell survival in response to ionizing radiation and defines a target to overcome intrinsic tumor radioresistance
Siva Karthik Varanasi, Ph.D.
Salk Inst for Biological Studies
PROJECT: Evaluating the role of bile acids as a metabolic checkpoint of anti-tumor T cell Hepatocellular Carcinoma
Yuanyuan Xie, Ph.D.
Regents of the Univ of Colorado
PROJECT: Elucidating the functional and genomic impact of retrocopies on cancer
Joy Bianchi, M.D.
NYU Langone Health
PROJECT: Targeting copy number alterations to overcome immune evasion in melanoma
Shixin Ma, Ph.D.
The Salk Inst for Biological Studies
PROJECT: Metabolically harnessing anti-tumor CD8 T cells at epigenetic level
Haopeng Xiao, Ph.D.
Dana-Farber Cancer Institute
PROJECT: Proteomic approaches to investigate Redox control in cancer
Siang-Boon Koh, Ph.D.
Massachusetts General Hospital Cancer Center
PROJECT: Synergistic targeting of DNA damage response and EMT pathways to reverse RASAL2-driven chemoresistance